Literature DB >> 30212043

Outcome of 6 months MBMDT in MB patients in Bangladesh- preliminary results.

C Ruth Butlin, David Pahan, Aung Kya Jai Maug, Stephen Withington, Peter Nicholls, Khorshed Alam, M D Abdul Hamid Salim.   

Abstract

Introduction: Duration of leprosy treatment remains long and difficult to complete in resource poor areas. Studies suggest that shortening duration of therapy for MB patients to 6 months may be possible.
Methods: New MB patients in 2005 in two NGO projects in Bangladesh were treated with 6 months WHO MB MDT and the rate of relapse and fall in BI on slit skin smear during follow up to date were compared with a control group treated for 12 months the previous year.
Results: 1612 patients were enrolled in the trial, and the average duration of follow up was over 7 years after diagnosis. During 11,425 PYAR of follow-up, no relapses were detected, by bacteriological or clinical criteria, in the 918 patients in the 6 months MB MDT group, nor in the 694 patients in the control group. Rate of decline of BI in those who were smear positive was not significantly different between groups.
Conclusion: The data does not suggest that shortening duration of treatment from 2 months to 6 months MDT for MB leprosy patients leads to increased rates of relapse.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 30212043

Source DB:  PubMed          Journal:  Lepr Rev        ISSN: 0305-7518            Impact factor:   0.537


  4 in total

Review 1.  Leprosy: current situation, clinical and laboratory aspects, treatment history and perspective of the uniform multidrug therapy for all patients.

Authors:  Rossilene Conceição da Silva Cruz; Samira Bührer-Sékula; Maria Lúcia F Penna; Gerson Oliveira Penna; Sinésio Talhari
Journal:  An Bras Dermatol       Date:  2017 Nov-Dec       Impact factor: 1.896

2.  Uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): Results of an open label, randomized and controlled clinical trial, among multibacillary patients.

Authors:  Gerson Oliveira Penna; Samira Bührer-Sékula; Lígia Regina Sansigolo Kerr; Mariane Martins de Araújo Stefani; Laura Cunha Rodrigues; Marcelo Grossi de Araújo; Andrea Machado Coelho Ramos; Ana Regina Coelho de Andrade; Maurício Barcelos Costa; Patricia Sammarco Rosa; Heitor de Sá Gonçalves; Rossilene Cruz; Maurício Lima Barreto; Maria Araci de Andrade Pontes; Maria Lúcia Fernandes Penna
Journal:  PLoS Negl Trop Dis       Date:  2017-07-13

Review 3.  Treatment and Evaluation Advances in Leprosy Neuropathy.

Authors:  Gigi J Ebenezer; David M Scollard
Journal:  Neurotherapeutics       Date:  2021-11-19       Impact factor: 7.620

4.  Three drugs are unnecessary for treating paucibacillary leprosy-A critique of the WHO guidelines.

Authors:  Diana N J Lockwood; Saba Lambert; Aparna Srikantam; Joydeepa Darlong; V V Pai; C Ruth Butlin; Barbara de Barros; Edessa Negera; Stephen L Walker
Journal:  PLoS Negl Trop Dis       Date:  2019-10-31
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.